Genelux Corporation to Participate in a Fireside Chat at Piper Sandler 37th Annual Healthcare Conference
Genelux (NASDAQ: GNLX) announced that Thomas Zindrick, President, CEO and Chairman, and Matt Pulisic, CFO, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025 at 12:00 p.m. ET in New York.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Genelux (NASDAQ: GNLX) announced that Thomas Zindrick, President, CEO and Chairman, and Matt Pulisic, CFO, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025 at 12:00 p.m. ET in New York.
A live webcast will be available during the event and an archived replay will be posted on the company's investor website at https://investors.genelux.com/.
Details
News Market Reaction – GNLX
On Nov 26, the day this news came out, GNLX closed 5.67% above the previous close.
Data tracked by StockTitan Argus for the Nov 26 session.
Key Figures
- Conference date
- December 3, 2025
- Scheduled Piper Sandler 37th Annual Healthcare Conference fireside chat
- Event time
- 12:00 p.m. ET
- Scheduled start time of fireside chat in New York
Historical Context
-
Announcement of Piper Sandler healthcare conference fireside chat and webcast access.
-
Q3 2025 financials, cash of $21.0M, and updated trial timelines.
-
H.C. Wainwright fireside chat and investor meetings announcement.
-
Q2 2025 results, $28.1M cash and OnPrime Phase 3 timing.
-
Appointment of Eric Groen as General Counsel and Head of Business Development.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WESTLAKE VILLAGE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board and Matt Pulisic, Chief Financial Officer, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025 at 12:00 p.m. ET in New York, NY.
A live webcast of the fireside chat can be found here. Following the live webcast, an archived replay will be available on the Company’s website https://investors.genelux.com/.
About Genelux Corporation
Genelux is a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Olvi-Vec currently is being evaluated in two U.S.-based clinical trials: OnPrime/GOG-3076, a multi-center, randomized, open-label Phase 3 registrational trial evaluating the efficacy and safety of Olvi-Vec in combination platinum-doublet + bevacizumab compared with physician's choice of chemotherapy and bevacizumab in patients with platinum-resistant/refractory ovarian cancer; and, VIRO-25, a multi-center, randomized, open-label Phase 2 trial evaluating the efficacy and safety of Olvi-Vec & platinum-doublet + physician's choice of immune checkpoint inhibitor compared to docetaxel in non-small-cell lung cancer. Additionally, Olvi-Vec currently is being evaluated for dose selection in Olvi-Vec-SCLC-202, a China-based, multi-center, open label Phase 1b trial evaluating the efficacy and safety of Olvi-Vec & platinum-doublet in recurrent small-cell lung cancer. The core of Genelux's discovery and development efforts revolves around its proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. For more information, please visit www.genelux.com and follow us on X @Genelux_Corp and on LinkedIn.
Investor Contact
Austin Murtagh
Precision AQ
austin.murtagh@precisionaq.com
Media Contact
Ashley Murphy
Precision AQ
ashley.murphy@precisionaq.com
Source: Genelux Corporation
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.